179 related articles for article (PubMed ID: 33045017)
1. A predictive Bayesian network that risk stratifies patients undergoing Barrett's surveillance for personalized risk of developing malignancy.
Bradley A; Sami S; N G H; Macleod A; Prasanth M; Zafar M; Hemadasa N; Neagle G; Rosindell I; Apollos J
PLoS One; 2020; 15(10):e0240620. PubMed ID: 33045017
[TBL] [Abstract][Full Text] [Related]
2. Does Risk of Progression from Barrett's Esophagus to Esophageal Adenocarcinoma Change Based on the Number of Non-dysplastic Endoscopies?
Kunzmann AT; Coleman HG; Johnston BT; Turkington RC; McManus D; Anderson LA; Thrift AP
Dig Dis Sci; 2021 Jun; 66(6):1965-1973. PubMed ID: 32734400
[TBL] [Abstract][Full Text] [Related]
3. Derivation of genetic biomarkers for cancer risk stratification in Barrett's oesophagus: a prospective cohort study.
Timmer MR; Martinez P; Lau CT; Westra WM; Calpe S; Rygiel AM; Rosmolen WD; Meijer SL; Ten Kate FJ; Dijkgraaf MG; Mallant-Hent RC; Naber AH; van Oijen AH; Baak LC; Scholten P; Böhmer CJ; Fockens P; Maley CC; Graham TA; Bergman JJ; Krishnadath KK
Gut; 2016 Oct; 65(10):1602-10. PubMed ID: 26104750
[TBL] [Abstract][Full Text] [Related]
4. Surveillance in Barrett's esophagus: an audit of practice.
Ajumobi A; Bahjri K; Jackson C; Griffin R
Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
[TBL] [Abstract][Full Text] [Related]
5. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Med J Aust; 2004 Apr; 180(8):387-91. PubMed ID: 15089728
[TBL] [Abstract][Full Text] [Related]
6. External validation of a model to determine risk of progression of Barrett's oesophagus to neoplasia.
Kunzmann AT; Thrift AP; Johnston BT; McManus DT; Gavin AT; Turkington RC; Coleman HG
Aliment Pharmacol Ther; 2019 May; 49(10):1274-1281. PubMed ID: 30950101
[TBL] [Abstract][Full Text] [Related]
7. Esophageal adenocarcinoma in a first-degree relative increases risk for esophageal adenocarcinoma in patients with Barrett's esophagus.
Tofani CJ; Gandhi K; Spataro J; Yoo J; Murphy M; Mohan N; Daitch Z; Shah A; Janowski R; Huntley C; Dabbish N; Keith S; Coben R; Cohen S; Kastenberg D; Infantolino A
United European Gastroenterol J; 2019 Mar; 7(2):225-229. PubMed ID: 31080607
[TBL] [Abstract][Full Text] [Related]
8. Barrett's oesophagus: Current controversies.
Amadi C; Gatenby P
World J Gastroenterol; 2017 Jul; 23(28):5051-5067. PubMed ID: 28811703
[TBL] [Abstract][Full Text] [Related]
9. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry.
O'Connor JB; Falk GW; Richter JE
Am J Gastroenterol; 1999 Aug; 94(8):2037-42. PubMed ID: 10445525
[TBL] [Abstract][Full Text] [Related]
10. Length of Barrett's oesophagus and cancer risk: implications from a large sample of patients with early oesophageal adenocarcinoma.
Pohl H; Pech O; Arash H; Stolte M; Manner H; May A; Kraywinkel K; Sonnenberg A; Ell C
Gut; 2016 Feb; 65(2):196-201. PubMed ID: 26113177
[TBL] [Abstract][Full Text] [Related]
11. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
Weston AP; Badr AS; Hassanein RS
Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
[TBL] [Abstract][Full Text] [Related]
12. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
[TBL] [Abstract][Full Text] [Related]
13. Cancer Risk in Barrett's Esophagus: A Clinical Review.
Beydoun AS; Stabenau KA; Altman KW; Johnston N
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37046992
[TBL] [Abstract][Full Text] [Related]
14. Predictors of dysplastic and neoplastic progression of Barrett’s esophagus.
Alnasser S; Agnihotram R; Martel M; Mayrand S; Franco E; Ferri L
Can J Surg; 2019 Apr; 62(2):93-99. PubMed ID: 30907564
[TBL] [Abstract][Full Text] [Related]
15. Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus.
Incarbone R; Bonavina L; Saino G; Bona D; Peracchia A
Surg Endosc; 2002 Feb; 16(2):263-6. PubMed ID: 11967675
[TBL] [Abstract][Full Text] [Related]
16. Barrett's esophagus: clinical characteristics.
Reynolds JC; Rahimi P; Hirschl D
Gastroenterol Clin North Am; 2002 Jun; 31(2):441-60. PubMed ID: 12134612
[TBL] [Abstract][Full Text] [Related]
17. Barrett's oesophagus: frequency and prediction of dysplasia and cancer.
Falk GW
Best Pract Res Clin Gastroenterol; 2015 Feb; 29(1):125-38. PubMed ID: 25743461
[TBL] [Abstract][Full Text] [Related]
18. Surveillance for Barrett's oesophagus: results from a programme in Northern Ireland.
Murphy SJ; Dickey W; Hughes D; O'Connor FA
Eur J Gastroenterol Hepatol; 2005 Oct; 17(10):1029-35. PubMed ID: 16148547
[TBL] [Abstract][Full Text] [Related]
19. Determination of risk for Barrett's esophagus and esophageal adenocarcinoma.
Thrift AP
Curr Opin Gastroenterol; 2016 Jul; 32(4):319-24. PubMed ID: 27276368
[TBL] [Abstract][Full Text] [Related]
20. [Surveillance for Barrett's oesophagus: worthwhile?].
Kastelein F; Kuipers EJ
Ned Tijdschr Geneeskd; 2012; 156(49):A5497. PubMed ID: 23218039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
